Back to Search Start Over

Sebaceous carcinoma: evidence-based clinical practice guidelines

Authors :
Tim Ramsay
Kishwer S. Nehal
Abigail Waldman
Veronica Rotemberg
Michael K. Wong
Ryan C. Kelm
Christopher K. Bichakjian
Naomi Lawrence
Jeremy S. Bordeaux
Bita Esmaeli
Daniel B. Eisen
Emily Poon
Y. Gloria Xu
Conway C. Huang
Joshua L. Owen
Hakan Demirci
Siegrid S. Yu
David T. Tse
Brian Petersen
Nour Kibbi
Faramarz H. Samie
Diana Bolotin
Ian A. Maher
Joseph F. Sobanko
Margaret W. Mann
Kira Minkis
Kelly A. Reynolds
Isaac M. Neuhaus
Sandeep Samant
Stephen Y. Lai
John Kim
William G. Stebbins
Sherrif F. Ibrahim
Timothy M. Kuzel
Nancy L. Cho
Todd V. Cartee
J. Regan Thomas
Jordan V Wang
Ramona Behshad
Bharat B. Mittal
Jennifer N. Choi
Justin J. Leitenberger
Ally Khan Somani
Carol L. Shields
Murad Alam
Nathalie C. Zeitouni
Erica H. Lee
Brandon Worley
Sunandana Chandra
David M. Ozog
Sabah Servaes
Nicholas Golda
S. Brian Jiang
Christopher A. Barker
Scott H. Bradshaw
Thuzar M. Shin
Valencia Thomas
Source :
The Lancet. Oncology. 20(12)
Publication Year :
2019

Abstract

Sebaceous carcinoma usually occurs in adults older than 60 years, on the eyelid, head and neck, and trunk. In this Review, we present clinical care recommendations for sebaceous carcinoma, which were developed as a result of an expert panel evaluation of the findings of a systematic review. Key conclusions were drawn and recommendations made for diagnosis, first-line treatment, radiotherapy, and post-treatment care. For diagnosis, we concluded that deep biopsy is often required; furthermore, differential diagnoses that mimic the condition can be excluded with special histological stains. For treatment, the recommended first-line therapy is surgical removal, followed by margin assessment of the peripheral and deep tissue edges; conjunctival mapping biopsies can facilitate surgical planning. Radiotherapy can be considered for cases with nerve or lymph node involvement, and as the primary treatment in patients who are ineligible for surgery. Post-treatment clinical examination should occur every 6 months for at least 3 years. No specific systemic therapies for advanced disease can be recommended, but targeted therapies and immunotherapies are being developed.

Details

ISSN :
14745488
Volume :
20
Issue :
12
Database :
OpenAIRE
Journal :
The Lancet. Oncology
Accession number :
edsair.doi.dedup.....c5f6c7c8bce25816670b397dc701ab6c